Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
暂无分享,去创建一个
A. Blauvelt | C. Leonardi | Ines Brueckmann | P. Wiland | N. Gaylis | J. Jauch-Lembach | A. Balfour | L. Lemke | Teodora Festini | S. Hachaichi